Halozyme Therapeutics, Inc. filings document the company's drug-delivery business, royalty-based collaboration model, governance actions and capital-market disclosures. 8-K reports cover financial results and guidance, executive officer appointments and compensation arrangements, bylaw amendments, and annual meeting voting results.
Proxy materials describe board elections, executive compensation, equity awards, auditor ratification and stockholder voting mechanics. Filings also provide formal disclosure around ENHANZE, Hypercon and Surf Bio technology portfolio updates, partnered commercial products, and acquisition-related operating updates when reported by the company.
HALOZYME THERAPEUTICS, INC. (HALO) director Matthew L. Posard reported selling a total of 18,996 shares of common stock on September 16, 2026 in four open-market transactions. The sales, at weighted average prices between about $106 and $109 per share, were made under a Rule 10b5-1 trading plan adopted June 15, 2026.
HALOZYME THERAPEUTICS, INC. (HALO) reports that director Matthew Posard has filed a notice to sell 34,226 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC. The shares were acquired via vesting of restricted stock units between June 5, 2015 and May 5, 2022.
The notice lists an aggregate market value of $3,636,512.50 for the shares to be sold and indicates that there are 113,498,000 shares of common stock outstanding.
Halozyme Therapeutics, Inc. (HALO) plans a private offering, subject to market conditions and other factors, of $1.05 billion aggregate principal amount of convertible senior notes due 2033, with an expected $150 million option for initial purchasers to buy additional notes. The notes will be senior, unsecured obligations maturing on October 1, 2033, convertible under specified conditions before April 1, 2033 and at any time thereafter until shortly before maturity. Halozyme expects to enter into capped call transactions to offset potential conversion dilution and plans to use part of the net proceeds to pay for these capped calls and to repurchase portions of its existing 0.25% convertible notes due 2027 and 1.00% convertible notes due 2028, with the remainder for general corporate purposes and possible future note repurchases or repayments.
HALOZYME THERAPEUTICS, INC. (HALO) reported that President and CEO Helen Torley exercised stock options for 60,000 shares of common stock at an exercise price of $18.41 per share over September 9–11, 2026, and sold 60,000 shares at weighted average prices around $107 per share under a pre-arranged Rule 10b5-1 trading plan.
HALOZYME THERAPEUTICS, INC. (HALO) reported that director Dannielle Appelhans received equity-based compensation on September 1, 2026. She was granted 1,161 Restricted Stock Units, each representing one common share, and options to purchase 1,778 shares of common stock at an exercise price of $107.72 per share. Both the RSUs and the stock options are scheduled to vest in full on the date of Halozyme’s 2027 annual meeting of stockholders. No Rule 10b5-1 trading plan is reported for these awards.
HALOZYME THERAPEUTICS, INC. (HALO) filed an initial statement of beneficial ownership for director Dannielle Appelhans. The Form 3 indicates her status as a director but does not report any specific equity holdings or transactions at this time. The filing also includes an Exhibit 24 Power of Attorney authorization.
HALOZYME THERAPEUTICS, INC. (HALO) reported that President and CEO Helen Torley exercised stock options and sold common shares under a pre-arranged Rule 10b5-1 trading plan. Over August 17–19, 2026, she exercised options for 60,000 shares at $18.41 per share and sold 60,000 common shares in multiple open-market transactions at weighted-average prices generally between the high $90s and about $108 per share. The options exercised were part of a ten-year grant originally awarded in February 2018 and expiring in February 2028.
Halozyme Therapeutics, Inc. (HALO) reported a board change. On August 14, 2026, Dannielle Appelhans was elected to the company’s Board of Directors. She joins the class of directors whose terms end at the 2028 annual meeting of stockholders and was not initially assigned to any board committee.
Appelhans will receive cash retainers plus restricted stock and stock option awards under Halozyme’s standard director compensation program for non-employee directors, as previously described in the proxy statement for the 2026 annual meeting held on May 5, 2026. The company states there are no special arrangements related to her election and no related person transactions with her.
Halozyme Therapeutics insider Helen Torley filed a Form 144 indicating a proposed sale of 240,000 shares of common stock through J.P. Morgan Securities LLC, with an aggregate market value of $23,678,400 as of 08/17/2026. The filing lists 113,498,000 shares of Halozyme common stock outstanding. It also reports prior sales during the past three months totaling 51,923 shares of common stock for aggregate proceeds of $3,523,398 across four transactions.
Halozyme Therapeutics filed a Form 144 indicating an affiliate’s intent to sell common stock through Morgan Stanley Smith Barney LLC’s Executive Financial Services group at 1 New York Plaza, New York. The notice reflects planned cash sales tied to stock option exercises on August 11, 2026, including transactions for 32,659, 5,277, and 3,766 shares of common stock.